Phosphorylated Tau 217 Varies With Kidney Function Even Without Chronic Kidney Disease
- 1The University of Melbourne
Abstract
ImportancePlasma phosphorylated tau 217 (p-tau217) is entering clinical use with fixed diagnostic threshold that do not account for kidney function. Chronic kidney disease (defined as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2), raises plasma p-tau217 concentrations and can produce false positive results. It remains unclear whether milder reductions in kidney function, above the CKD threshold, have the same effect.
ObjectiveTo determine whether plasma p-tau217 is elevated with mildly reduced kidney function, above the chronic kidney disease threshold, in adults without neurological disease.
DesignCross-sectional analysis of a cohort enrolled between 2023 and 2025 and biomarker analysis blinded to clinical data.
SettingTwo private psychiatric inpatient facilities in Australia.
ParticipantsAdults admitted with psychiatric disorders and free of neurological disease.
ExposureseGFR calculated from serum creatinine using the CKD-EPI 2021 equation.
Main Outcomes and MeasuresPlasma p-tau217, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), measured on the Simoa platform. Multivariable linear regression compared eGFR groups (< 60, 60 to 90, and [≥] 90 mL/min/1.73 m2), adjusted for age, BMI, and sex.
ResultsAmong 180 participants (median age, 50.5 years [IQR, 38.0-61.5]; 94 [52%] female), eGFR was [≥] 90 mL/min/1.73 m2 in 106 (59%), 60 to 90 in 61 (34%), and < 60 in 13 (7.2%). Compared with an eGFR [≥] 90, plasma p-tau217 was 36% higher in both the 60 to < 90 group ({beta} = 0.42 [95% CI: 0.11, 0.74]; P = .008) and 116% higher in the < 60 group ({beta} = 1.05 [95% CI: 0.43, 1.72]; P = .002). Plasma NfL and GFAP were elevated in the < 60 group but differences in the 60 to < 90 group did not reach significance. Modelled continuously, plasma p-tau217 was 9.5% lower per 10 mL/min/1.73 m2 higher eGFR (95% CI: 3.3%, 15.4%).
Conclusions and RelevancePlasma p-tau217 was elevated in adults with mildly reduced kidney function, above the CKD threshold, in a cohort free of neurological disease. Kidney function across its full range should be incorporated into plasma p-tau217 reference ranges and clinical interpretation to reduce false positive and false negative results.
KEY POINTSO_ST_ABSQuestionC_ST_ABSIs plasma p-tau217 elevated at mildly reduced kidney function, above the chronic kidney disease (CKD) threshold?
FindingsIn this cross-sectional study of 180 inpatients free of neurological disease, plasma p-tau217 was 36% higher in participants with an estimated glomerular filtration rate (eGFR) between 60 and 90 mL/min/1.73 m2, and 116% higher in those below 60, compared with those at 90 or above.
MeaningGiven that plasma p-tau217 varies with kidney function across its range, not only in CKD, eGFR should be incorporated into reference ranges and the interpretation of results to reduce false positive and false negative findings.
Related
- Kidney Function Trajectories in Patients with and Without Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement: A Single-Retrospective Cohort Study
- Nicotine dependence and physical function: a comparison between current smokers with and without chronic obstructive pulmonary disease who seek cognitive-behavioral therapy
- Non-invasive assessment of estimated glomerular filtration rate using lens autofluorescence in a population without chronic kidney disease
- Telephone-administered semantic fluency task in older adults without dementia in relation to in-person testing and plasma phosphorylated tau-217
- Changes in hepatic functional reserve and renal function during hospitalization in patients with chronic liver disease : A retrospective observational study of inpatient rehabilitation
BibTeX
@misc{kang2026phosphorylated,
title = {{Phosphorylated Tau 217 Varies With Kidney Function Even Without Chronic Kidney Disease}},
author = {M. J. Y. Kang and T. Borchard and M. M. Mielke and H. Zetterberg and M. Hopwood and P. B. Mitchell and D. Eratne and D. Velakoulis},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.18.26365853},
url = {https://www.medrxiv.org/content/10.64898/2026.10.18.26365853v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Phosphorylated Tau 217 Varies With Kidney Function Even Without Chronic Kidney Disease
AU - M. J. Y. Kang
AU - T. Borchard
AU - M. M. Mielke
AU - H. Zetterberg
AU - M. Hopwood
AU - P. B. Mitchell
AU - D. Eratne
AU - D. Velakoulis
PY - 2026
DA - 2026/10/18
PB - medRxiv
DO - 10.64898/2026.10.18.26365853
UR - https://www.medrxiv.org/content/10.64898/2026.10.18.26365853v1
AB - ImportancePlasma phosphorylated tau 217 (p-tau217) is entering clinical use with fixed diagnostic threshold that do not account for kidney function. Chronic kidney disease (defined as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2), raises plasma p-tau217 concentrations and can produce false positive results. It remains unclear whether milder reductions in kidney function, above the CKD threshold, have the same effect. ObjectiveTo determine whether plasma p-tau217 is elevated with mildly reduced kidney function, above the chronic kidney disease threshold, in adults without neurological disease. DesignCross-sectional analysis of a cohort enrolled between 2023 and 2025 and biomarker analysis blinded to clinical data. SettingTwo private psychiatric inpatient facilities in Australia. ParticipantsAdults admitted with psychiatric disorders and free of neurological disease. ExposureseGFR calculated from serum creatinine using the CKD-EPI 2021 equation. Main Outcomes and MeasuresPlasma p-tau217, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), measured on the Simoa platform. Multivariable linear regression compared eGFR groups (< 60, 60 to 90, and [≥] 90 mL/min/1.73 m2), adjusted for age, BMI, and sex. ResultsAmong 180 participants (median age, 50.5 years [IQR, 38.0-61.5]; 94 [52%] female), eGFR was [≥] 90 mL/min/1.73 m2 in 106 (59%), 60 to 90 in 61 (34%), and < 60 in 13 (7.2%). Compared with an eGFR [≥] 90, plasma p-tau217 was 36% higher in both the 60 to < 90 group ({beta} = 0.42 [95% CI: 0.11, 0.74]; P = .008) and 116% higher in the < 60 group ({beta} = 1.05 [95% CI: 0.43, 1.72]; P = .002). Plasma NfL and GFAP were elevated in the < 60 group but differences in the 60 to < 90 group did not reach significance. Modelled continuously, plasma p-tau217 was 9.5% lower per 10 mL/min/1.73 m2 higher eGFR (95% CI: 3.3%, 15.4%). Conclusions and RelevancePlasma p-tau217 was elevated in adults with mildly reduced kidney function, above the CKD threshold, in a cohort free of neurological disease. Kidney function across its full range should be incorporated into plasma p-tau217 reference ranges and clinical interpretation to reduce false positive and false negative results. KEY POINTSO_ST_ABSQuestionC_ST_ABSIs plasma p-tau217 elevated at mildly reduced kidney function, above the chronic kidney disease (CKD) threshold? FindingsIn this cross-sectional study of 180 inpatients free of neurological disease, plasma p-tau217 was 36% higher in participants with an estimated glomerular filtration rate (eGFR) between 60 and 90 mL/min/1.73 m2, and 116% higher in those below 60, compared with those at 90 or above. MeaningGiven that plasma p-tau217 varies with kidney function across its range, not only in CKD, eGFR should be incorporated into reference ranges and the interpretation of results to reduce false positive and false negative findings.
ER -